BIIB122

Overview

Overview

BIIB122, formerly known as DNL151, is a highly selective, brain-penetrant small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) developed through a collaboration between Biogen and Denali Therapeutics. Originally discovered and advanced through Phase 1 clinical trials by Denali, BIIB122 was subsequently licensed to Biogen in 2023 as part of a broader neuroscience partnership. The compound represents one of the most advanced LRRK2 inhibitor programs in clinical development for Parkinson's disease["@dnl151"][@biogen].

LRRK2 is one of the most common genetic risk factors for Parkinson's disease, with gain-of-function mutations causing increased kinase activity that leads to impaired lysosomal function, altered autophagy, neuroinflammation, and ultimately dopaminergic neuron death. BIIB122 aims to restore normal LRRK2 activity through reversible kinase inhibition, potentially slowing or halting disease progression rather than merely treating symptoms["@lrrk2biology"].

<div class="infobox infobox-entity">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">BIIB122 (DNL151)</th></tr>
<tr><td><strong>Drug Name</strong></td><td>BIIB122 (DNL151)</td></tr>
<tr><td><strong>Target</strong></td><td>LRRK2 (Leucine-Rich Repeat Kinase 2)</td></tr>
<tr><td><strong>Company</strong></td><td>Biogen / Denali Therapeutics</td></tr>
<tr><td><strong>Indication</strong></td><td>Parkinson's Disease</td></tr>
<tr><td><strong>Mechanism</strong></td><td>Reversible, selective LRRK2 kinase inhibition</td></tr>
<tr><td><strong>Route</strong></td><td>Oral (tablet)</td></tr>
<tr><td><strong>Development Phase</strong></td><td>Phase 2</td></tr>
</table>
</div>

LRRK2 Biology and Parkinson's Disease

LRRK2 Structure and Function

LRRK2 is a large multidomain protein (2527 amino acids, ~286 kDa) with complex architecture that includes multiple functional domains[@lrrk2structure]:

The kinase domain is the therapeutic target for small molecule inhibitors like BIIB122. It catalyzes the phosphorylation of multiple substrates, including:

• Rab GTPases (Rab10, Rab8A, Rab12, Rab29)
• Auto-regulatory sites (Ser1292 autophosphorylation)
• Rotatin, AEP, and other neuronal substrates

LRRK2 Mutations in Parkinson's Disease

Over 100 LRRK2 pathogenic variants have been identified, with the G2019S mutation being the most common:

| Mutation | Effect | Prevalence |
|----------|--------|------------|
| G2019S | Increased kinase activity (~2-fold) | ~5% familial PD, ~1% sporadic PD |
| R1441C/G/H | Decreased GTPase activity | ~3-5% familial PD |
| N1437H | Increased kinase activity | Rare |
| Y1699C | Altered protein function | Rare |

The G2019S mutation, located in the kinase domain activation loop, is particularly amenable to pharmacological inhibition, as it results in a kinase that is hyperactive but structurally similar to wild-type[@g2019s].

Pathogenic Mechanisms

LRRK2 gain-of-function mutations cause neurodegeneration through multiple mechanisms:

1. Lysosomal Dysfunction

LRRK2 regulates lysosomal biogenesis and function through phosphorylation of Rab proteins. Mutant LRRK2 leads to[@lysosomal]:

• Impaired autophagosome-lysosome fusion
• Decreased clearance of alpha-synuclein aggregates
• Accumulation of lipofuscin
• Lysosomal membrane destabilization

2. Neuroinflammation

LRRK2 is highly expressed in microglia, where its activity modulates inflammatory responses[@neuroinflammation]:

• Enhanced pro-inflammatory cytokine production
• Increased microglial phagocytosis
• Elevated expression of disease-associated microglial markers
• Neurotoxic microglial phenotypes

3. Mitochondrial Dysfunction

LRRK2 affects mitochondrial quality control:

• Impaired mitophagy through Rab32 and Rab39B interactions
• Reduced mitochondrial dynamics
• Increased oxidative stress

4. Synaptic Dysfunction

LRRK2 regulates synaptic vesicle trafficking:

• Altered dopamine release
• Impaired synaptic vesicle recycling
• Reduced synaptic plasticity

Mechanism of Action

BIIB122 Pharmacology

BIIB122 is a highly selective LRRK2 kinase inhibitor with the following characteristics[@dnl151][@pkpd]:

Mechanism of Therapeutic Benefit

By inhibiting LRRK2 kinase activity, BIIB122[@preclinical]:

Biomarker Strategy

BIIB122 development employs pharmacodynamic biomarkers to confirm target engagement[@biomarkers]:

• LRRK2 pSer1292: Autophosphorylation marker in blood cells
• Rab10 pThr73: Direct LRRK2 substrate phosphorylation
• NfL (Neurofilament Light Chain): Neuronal injury marker
• Alpha-synuclein in CSF: Disease progression marker

Clinical Development

LUMA Phase 1 Study

The LUMA Phase 1 trial evaluated single and multiple ascending doses of BIIB122 in healthy volunteers[@luma]:

| Parameter | Results |
|-----------|---------|
| Single doses tested | 10-400 mg |
| Multiple doses tested | 25-200 mg daily for 14 days |
| Maximum tolerated dose | Not reached (good safety margin) |
| Target engagement | Dose-dependent LRRK2 pSer1292 inhibition |
| Pharmacokinetics | Linear PK, Tmax 2-4 hours, half-life 8-12 hours |
| Adverse events | Mild-moderate, mainly GI (nausea, diarrhea) |

Key findings:

• >80% LRRK2 inhibition achieved at doses ≥100 mg
• No serious adverse events
• Low dropout rate (<5%)
• Supports once-daily or twice-daily dosing

LIGHTHOUSE Phase 2 Trial

The LIGHTHOUSE trial (NCT05477376) is evaluating BIIB122 in patients with Parkinson's disease carrying LRRK2 pathogenic mutations[@lighthouse]:

Study Design:

• Randomized, double-blind, placebo-controlled
• 12-month treatment period
• Primary endpoint: Change in MDS-UPDRS Part III (motor) score
• Key secondary endpoints: Non-motor symptoms, biomarkers

• Age 40-80 years
• Confirmed LRRK2 pathogenic mutation (G2019S, R1441C/G/H, etc.)
• Hoehn & Yahr stage 1-3
• On stable dopaminergic therapy

SUNRISE Phase 2 Trial

The SUNRISE trial (NCT05879852) is evaluating BIIB122 in patients with sporadic (non-genetic) Parkinson's disease[@sunrise]:

Study Design:

• Similar design to LIGHTHOUSE
• Enrolling patients without LRRK2 mutations
• Focus on understanding efficacy in broader PD population

• Even wild-type LRRK2 may have elevated activity in some sporadic PD patients
• LRRK2 inhibition may benefit non-mutation carriers through anti-inflammatory effects
• Informs potential broad label if successful

Ongoing and Planned Studies

| Trial | Phase | Population | Status | Primary Endpoint |
|-------|-------|------------|--------|------------------|
| LUMA | Phase 1 | Healthy volunteers | Completed | Safety, PK, PD |
| LIGHTHOUSE | Phase 2 | LRRK2-associated PD | Recruiting | MDS-UPDRS III |
| SUNRISE | Phase 2 | Sporadic PD | Recruiting | MDS-UPDRS III |
| Open-label extension | Long-term | All participants | Planned | Safety |

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Properties

BIIB122 exhibits favorable pharmacokinetic properties for chronic PD treatment[@pkpd]:

| Parameter | Value |
|-----------|-------|
| Oral bioavailability | Moderate (~40-60%) |
| Tmax | 2-4 hours |
| Half-life | 8-12 hours |
| Protein binding | Moderate (~70%) |
| Brain penetration | High (CSF/Plasma ratio ~0.3) |
| Metabolism | Hepatic (CYP3A4 primary) |
| Excretion | Primarily fecal |

Drug-Drug Interactions

• CYP3A4 inhibitors: May increase BIIB122 exposure (monitor closely)
• CYP3A4 inducers: May decrease BIIB122 exposure
• Levodopa/carbidopa: No significant interaction expected
• MAO-B inhibitors: No significant interaction expected

Pharmacodynamic Markers

The pharmacodynamic response is measured through[@biomarkers]:

Safety and Tolerability

Adverse Event Profile

Based on Phase 1 data, BIIB122 has demonstrated a favorable safety profile[@safety]:

| System Organ Class | Common AEs | Frequency |
|-------------------|------------|-----------|
| Gastrointestinal | Nausea, diarrhea | 15-25% |
| Nervous system | Headache, dizziness | 10-15% |
| General | Fatigue | 5-10% |
| Laboratory | Transient LFT elevations | <5% |

Key Safety Observations

• No dose-limiting toxicities identified in Phase 1
• No ARIA (amyloid-related imaging abnormalities) observed (unlike anti-amyloid antibodies)
• No peripheral edema (unlike some kinase inhibitors)
• No QT prolongation at therapeutic doses

Contraindications and Precautions

• Pregnancy: Contraindicated (no adequate data)
• Severe hepatic impairment: Use with caution (reduced clearance)
• Concomitant strong CYP3A4 inhibitors: Monitor closely

Comparison with Other LRRK2 Inhibitors

The LRRK2 inhibitor landscape includes several compounds in various development stages[@competitive]:

| Drug | Company | Phase | Key Differentiator |
|------|---------|-------|-------------------|
| BIIB122 (DNL151) | Biogen/Denali | Phase 2 | Leading position, broad pipeline |
| DNL343 | Denali | Phase 1 | CNS-penetrant, neuroprotective |
| MLi-2 | Merck | Preclinical | Tool compound |
| GZ161803 | Glenmark | Phase 1 | Oral, selective |

BIIB122's advantages include:

• Extensive clinical data (Phase 1 complete)
• Demonstrated brain penetration
• Favorable safety profile
• Strong development partnership (Biogen resources)

Competitive Landscape

LRRK2 Inhibitor Development

The LRRK2 inhibitor field has evolved significantly[@competitive]:

Other Disease-Modifying Approaches in PD

BIIB122 competes with other disease-modifying approaches:

| Approach | Examples | Mechanism |
|----------|----------|-----------|
| Alpha-synuclein targeting | PRX002, BIIB054, ABBV-951 | Antibody, ASO |
| GBA augmentation | Lucerstat, GZ/SAR402671 | Enzyme enhancement |
| Mitochondrial protection | Inosine, gene therapy | Antioxidants, mitophagy |
| Neuroinflammation | Azeliragon, NP-03 | Anti-inflammatory |

LRRK2 inhibition represents a unique mechanism addressing multiple pathogenic pathways simultaneously.

Therapeutic Implications

Potential Benefits

If successful, BIIB122 could provide:

Challenges and Limitations

• Timing of intervention: May be most effective early in disease course
• Biomarker selection: Unclear which patients will respond best
• Long-term safety: Need extended exposure data
• Combination therapy: Optimal regimen unclear

Future Directions

The development program may expand to[@combination]:

Cross-Links

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [LRRK2 Gene](/genes/lrrk2)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction-pathway)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
• [PINK1 Gene](/genes/pink1)
• [Parkin Gene](/genes/parkin)
• [G2019S Mutation](/entities/lrrk2-g2019s-mutation)
• [Substantia Nigra](/brain-regions/substantia-nigra)
• [Dopaminergic Neurons](/cell-types/dopamine-neurons-drd)

References

External Links

• [ClinicalTrials.gov: LIGHTHOUSE](https://clinicaltrials.gov/NCT05477376)
• [ClinicalTrials.gov: SUNRISE](https://clinicaltrials.gov/NCT05879852)
• [Biogen Pipeline](https://www.biogen.com)
• [Denali Therapeutics](https://www.denalitherapeutics.com)
• [LRRK2 Foundation](https://www.lrrk2.org)
• [Allen Human Brain Atlas](https://brain-map.org/)